All conditions
BPC-157 for other

General Recovery

Of the 1 unique stories with a clear outcome, 1 reported it helped (100%).

These are public YouTube testimonials, not clinical evidence. People who tried BPC-157 and got no result rarely post videos — read this as a sample of the positive end of the distribution.

Verdict
100
% positive
1 helped0 partial0 no help
What people tried
3 to 5 week sprints
Helped · significant3 to 5 week sprintsover 3 weeks
my recovery's been great, ability to train has been nothing like it's been in 10 years
What the science says

Related research

All papers →
Mechanistic· mouse, ratmedium
2025

BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on Józwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals 2025, 18, 185.

BPC-157 therapy targets angiogenesis and nitric oxide's cytotoxic actions while maintaining their essential protective functions, and exhibits anti-tumor potential and counteracts neurodegenerative diseases in animal models. The paper defends BPC-157's safety and efficacy against speculation of negative impacts.

Pharmaceuticals (Basel, Switzerland)· Sikiric P, Seiwerth S et al.
PubMed · PMID 41155565
Animal study· ratmedium
2023

Pentadecapeptide BPC 157 as Therapy for Inferior Caval Vein Embolization: Recovery of Sodium Laurate-Post-Embolization Syndrome in Rats.

This study found that BPC-157 therapy can resolve post-embolization syndrome in rats by activating collateral pathways and counteracting multiorgan failure. The therapy rapidly reversed the symptoms of the syndrome, including prime lung lesions and thromboemboli occluding lung vessels.

Pharmaceuticals (Basel, Switzerland)· Smoday IM, Krezic I et al.
PubMed · PMID 37895979
Animal study· ratmedium
2012

Pentadecapeptide BPC 157 reduces bleeding time and thrombocytopenia after amputation in rats treated with heparin, warfarin or aspirin.

The peptide BPC-157 reduced bleeding time and thrombocytopenia in rats treated with heparin, warfarin, or aspirin after amputation. BPC-157 also improved survival time in heparin-treated rats.

Thrombosis research· Stupnisek M, Franjic S et al.
PubMed · PMID 21840572
Review· nulllow
2021

BPC 157 as Potential Treatment for COVID-19.

This paper discusses the potential of BPC-157 as a treatment for COVID-19 based on its anti-inflammatory, cytoprotective, and endothelial-protective effects. The authors suggest that BPC-157 may improve clinical management of COVID-19, but note that further research is needed.

Medical hypotheses· Deek SA
PubMed · PMID 34798584